|Articles|January 1, 2020
- Pharmaceutical Executive-01-01-2020
- Volume 40
- Issue 1
Pharmaceutical Executive, January 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive January 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Pharm Exec’s 2020 Industry Outlookalmost 6 years ago
Sharing the Pricing Stage in 2020almost 6 years ago
Paving Bayer’s Future Pathalmost 6 years ago
Politics & Pricing to Shape Pharma Prospects in 2020almost 6 years ago
Pharma’s Brexit Routealmost 6 years ago
Is the Tail Wagging the Dog in Drug Market Entry?almost 6 years ago
A Happy New Year for European Pharma Policy?almost 6 years ago
Deeper Dive: Gene Therapy Manufacturingalmost 6 years ago
Country Report: ChinaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Report: Richard Pazdur Out as Director of CDER
2
Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma
3
Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients
4
Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy
5
